BioMedNewsBreaks

TuesdayFeb 14, 2023 11:51 am

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Forms US-Based Subsidiary with Focus to Expand Innovation Platforms

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the formation of a U.S.-based wholly owned subsidiary, Pearsanta Inc. The move intends to accelerate the expansion of Aditxt’s second program, AditxtScore(TM), through future strategic revenue and growth-oriented transactions. According to the update, Anthony Voorhies, currently the head of the AditxtScore(TM) division, will serve as president of Pearsanta. Voorhies has over 20 years of clinical diagnostics and healthtech industry experience and, under his leadership, the AditxtScore(TM) division has successfully grown from inception to commercialization and revenues in just…

Continue Reading

TuesdayFeb 14, 2023 11:42 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Launches New Program Targeting Unmet Medical Needs for Alcohol Misuse

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced the launch of a new research and development program focused on unmet medical needs for alcohol misuse. “Alcohol intoxication is a common presentation in many patients who visit hospital emergency rooms, and I see this during every one of my shifts,” said Dr. Albert Wong, a member of FSD Pharma’s expert advisory committee and a psychiatrist in the emergency department at the Centre…

Continue Reading

TuesdayFeb 14, 2023 11:31 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q3 Financial Report, Corporate Highlights

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is reporting on its third quarter performance as well as recent business highlights; the report is for the period ended Dec. 31, 2022. In the report, the company noted that it had received approval from an independent ethics committee in the Netherlands to begin the first-in-human dosing of its CYB004 through a protocol amendment to its ongoing phase 1 CYB004-E trial; CYB004 is the company’s proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule. The company is also making progress on its phase 1/2a clinical trial evaluating CYB003 for the potential treatment…

Continue Reading

MondayFeb 13, 2023 12:47 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Alzheimer’s

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent application for the use of its central nervous system (“CNS”) homing peptides to treat Alzheimer’s disease and the onset of dementia. Alzheimer’s has proven to be a progressive neurodegenerative disorder associated with the destruction of higher brain structures, such as those involved in cognition and memory function. The disease leads to declines and deficits in memory, learning, language and the ability to perform intentional and purposeful movements and is accompanied by concomitant behavioral, emotional,…

Continue Reading

ThursdayFeb 09, 2023 11:35 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receipt of No Objection Letter from Health Canada Is Focus of Recent InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has received a No Objection Letter from Health Canada. That letter and what it means was the focus of a recent InvestmentPitch Media video. In the video, InvestmentPitch Media’s Cassandra Bolinski discusses the company’s recent receipt of the letter, which provides regulatory approval for FSD Pharms to move forward with its phase 1 clinical trial of LUCID-21-302 or Lucid-MS. A novel drug candidate for the treatment of multiple…

Continue Reading

WednesdayFeb 08, 2023 2:24 pm

BioMedNewsBreaks – MetAlert Inc. (MLRT) Pushing Boundaries of Innovation

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, developed GPS SmartSole(R), a medical monitoring device integrated into an orthotic insole, facilitating discreet tracking and remote monitoring of those living with Alzheimer’s, dementia and autism, who have a tendency to wander and become lost. “The SmartSole enables tracking by utilizing a 4G cellular network and … can be configured to send alerts via email or text whenever someone enters or exits specific areas, giving caregivers the utmost peace of mind. MetAlert has further enhanced the capabilities of SmartSole by adding Wi-Fi and Bluetooth capabilities, creating…

Continue Reading

WednesdayFeb 08, 2023 12:47 pm

BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) Eyes Continued Growth of Patent Family for ThermoStem(R) Program

BioRestorative Therapies (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the European Patent Office has issued a notice of allowance for a patent application related to the company’s metabolic ThermoStem(R) program. “Our patent family for our ThermoStem program continues to grow as we receive additional patent grants in key markets,” said Lance Alstodt, the company’s CEO. “We are committed to the development of ThermoStem as a potential treatment for obesity and metabolic disorders, such as type 2 diabetes. This patent, which covers a manufacturing process for ThermoStem developed by BioRestorative’s scientists, enhances our ability…

Continue Reading

WednesdayFeb 08, 2023 11:16 am

BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) to Be Featured in Radius Research Webinar

India Globalization Capital (NYSE American: IGC) today announced that its CEO Ram Mukunda and PFO Claudia Grimaldi will be featured in an investor webinar hosted by Radius Research. Beginning at 12:30 p.m. ET on Friday, Feb. 10, Mukunda and Grimaldi will discuss the company’s phase 2 trial for its drug candidate IGC-AD1 in treating agitation in dementia patients suffering from Alzheimer’s. They will also participate in a question-and-answer session. Interested parties should visit https://ibn.fm/iVpOP to register for the webinar. To view the full press release, visit https://ibn.fm/xstH7 About India Globalization Capital Inc. IGC develops advanced cannabinoid-based formulations for treating diseases…

Continue Reading

TuesdayFeb 07, 2023 1:53 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partnering to Transform Health Care, Improve Patient Outcomes

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on inflammation. “Silo’s sponsored clinical trial with the Clinical & Translational Science Institute at UCSF aims to validate the use of psilocybin as a therapeutic by evaluating the effects of the compound on patients suffering from inflammatory disorders, including Parkinson’s disease, bipolar and chronic pain,” a recent article reads. “In addition to its partnership with UCSF, Silo Pharma is also evaluating its ketamine formulation, designated as SPC-14, through a…

Continue Reading

TuesdayFeb 07, 2023 12:13 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Health Canada Regulatory Approval to Move Forward with Phase 1 Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has received notification that it can move forward with its proposed phase 1 clinical trial in Canada. The notification came in the form of a No Objection Letter (“NOL”) from Health Canada. The letter gives FSD Pharma regulatory approval to proceed with its clinical trial of LUCID-21-302 (“Lucid-MS”), a novel drug candidate for the treatment of multiple sclerosis. The first-in-human clinical trial is designed to evaluate the safety…

Continue Reading